CILENGITIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME AND UNMETHYLATED MGMT GENE PROMOTER: SAFETY RUN-IN RESULTS FROM A RANDOMIZED, CONTROLLED, PHASE II STUDY (CORE)

被引：0
|
作者：
Mikkelsen, T. [1 ]
Nabors, L. B. [2 ]
Fink, K. [3 ]
Chan, M. [4 ]
Trusheim, J. [5 ]
Raval, S. [6 ,10 ]
Hicking, C. [7 ]
Henslee-Downey, J. [9 ]
Picard, M. [7 ]
Reardon, D. [8 ]
机构：
[1] Henry Ford Hlth Syst, Detroit, MI USA
[2] Univ Alabama, Neurooncol Program, Birmingham, AL USA
[3] Baylor Univ, Med Ctr, Dallas, TX USA
[4] Wake Forest Univ Hlth Sci, Winston Salem, NC USA
[5] Virginia Piper Canc Inst, Minneapolis, MN USA
[6] Monmouth Med Ctr, Long Branch, NJ USA
[7] Merck KGaA, Darmstadt, Germany
[8] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumour Ctr, Durham, NC USA
[9] EMD Serono Inc, Rockland, MA USA
[10] Garden State Neurol & Neurooncol, Long Branch, NJ USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：173 / 173
页数：1
相关论文
共 50 条
  • [21] Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) plus radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
    Reardon, David A.
    Kaley, Thomas Joseph
    Dietrich, Jorg
    Clarke, Jennifer Leigh
    Dunn, Gavin
    Lim, Michael
    Cloughesy, Timothy Francis
    Gan, Hui Kong
    Park, Andrew J.
    Schwarzenberger, Paul
    Ricciardi, Toni
    Macri, Mary J.
    Ryan, Aileen
    Venhaus, Ralph Rudolph
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] SAFETY RUN-IN RESULTS OF A PHASE I/II STUDY TO EVALUATE ATEZOLIZUMAB IN COMBINATION WITH CABOZANTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
    Weathers, Shiao-Pei
    Kamiya-Matsuoka, Carlos
    Majd, Nazanin
    Ashu, Alda
    Thompson, Chantell
    Gachimova, Evguenia
    Aaroe, Ashley
    Patel, Chirag
    Loghin, Monica
    O'Brien, Barbara
    Yung, W. K. Alfred
    Puduvalli, Vinay
    de Groot, John
    NEURO-ONCOLOGY, 2023, 25
  • [23] FINAL RESULTS OF THE MGMT UNMETHYLATED ARM OF PARADIGM-2: A PHASE I STUDY OF OLAPARIB AND RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Derby, S. J.
    Sweeting, L.
    Shad, S.
    Paterson, L.
    Stobo, J.
    Nowicki, S.
    Williamson, A.
    James, A.
    Short, S. C.
    McBain, C.
    Herbert, C.
    Powell, J.
    Kelly, C.
    Chalmers, A. J.
    NEURO-ONCOLOGY, 2023, 25
  • [24] Gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme (GBM): Preliminary results of a phase II study
    Fabi, Alessandra
    Mirri, Alessandra
    Pace, Andrea
    Felici, Alessandra
    Vidiri, Antonello
    Metro, Giulio
    Cognetti, Francesco
    Occhipinti, Emanuele
    Arcangeli, Giorgio
    Carapella, Carmine
    NEURO-ONCOLOGY, 2007, 9 (04) : 530 - 530
  • [25] CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma.
    Verschaeve, V.
    D'Hondt, L. A.
    Verbeke, L. M. J.
    Van Fraeyenhove, F.
    Du Four, S.
    Duerinck, J.
    Neyns, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] SAFETY RUN-IN RESULTS OF A PHASE I/II STUDY TO EVALUATE THE SAFETY AND CLINICAL EFFICACY OF ATEZOLIZUMAB (ATEZO; aPDL1) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Weathers, Shiao-Pei
    Kamiya-Matsuoka, Carlos
    Dervin, Shannon
    Yun, Cindy
    Loghin, Monica
    O'Brien, Barbara
    Harrison, Rebecca
    Yung, W. K. Alfred
    Penas-Prado, Marta
    de Groot, John
    NEURO-ONCOLOGY, 2018, 20 : 9 - 10
  • [27] An update of phase II results from RTOG 0211: A phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma multiforme
    Chakravarti, A.
    Berkey, B.
    Robins, I.
    Guha, A.
    Curran, W.
    Brachman, D.
    Shultz, C.
    Mehta, M.
    NEURO-ONCOLOGY, 2006, 8 (04) : 439 - 439
  • [28] Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation: Final results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.
    Stupp, Roger
    Hegi, Monika E.
    Goriia, Thierry
    Erridge, Sara
    Grujicic, Danica
    Steinbach, Joachim Peter
    Wick, Wolfgang
    Tarnawski, Rafal
    Nam, Do-Hyun
    Weyerbrock, Astrid
    Hau, Peter
    Taphoorn, Martin J. B.
    Nabors, Louis B.
    Reardon, David A.
    Van den Bent, Martin J.
    Perry, James R.
    Hong, Yong Kil
    Hicking, Christine
    Picard, Martin
    Weller, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme
    Athanassiou, H
    Synodinou, M
    Maragoudakis, E
    Paraskevaidis, M
    Verigos, C
    Misailidou, D
    Antonadou, D
    Saris, G
    Beroukas, K
    Karageorgis, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) : 2372 - 2377
  • [30] A PHASE 1 TRIAL OF IMMUNORADIOTHERAPY WITH THE IDO ENZYME INHIBITOR (BMS-986205) AND NIVOLUMAB IN PATIENTS WITH NEWLY DIAGNOSED MGMT PROMOTER UNMETHYLATED IDHWT GLIOBLASTOMA
    Lukas, Rimas
    Sachdev, Sean
    Kumthekar, Priya
    Dixit, Karan
    Grimm, Sean
    Gondi, Vinai
    Sharp, Laura
    Lezon, Ray
    James, David
    Lesniak, Maciej
    Stupp, Roger
    Wainwright, Derek
    NEURO-ONCOLOGY, 2021, 23 : 51 - 52
12345